Dietary Supplement Listing Act of 2026
- Bill Number
- S. 3677
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-01-15: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S259-260)
- Last Updated
- 2026-04-30T19:42:20Z
AI-Generated Summary
Purpose
The Dietary Supplement Listing Act of 2026 aims to increase transparency and public access to information about dietary supplements by requiring their manufacturers, packers, or distributors (referred to as the "responsible person") to submit detailed product listings to the Food and Drug Administration (FDA). This helps ensure that basic product details are centralized and searchable, without requiring FDA approval before marketing.
Key Provisions
- Listing Requirements: Starting 18 months after enactment (for products already on the market by January 1, 2027) or at the time of market introduction (for new products), responsible persons must submit listings to the FDA. These include:
- Product name, brand, flavors, and statement of identity.
- Contact details for the responsible person and, if foreign, their U.S. agent.
- An electronic copy of the product label.
- Full list of ingredients, including amounts per serving (except confidential amounts in proprietary blends), servings per container, directions for use, warnings, allergen statements, product form (e.g., tablets, gummies), and certain health claims on the label.
- Updates for changes within 30 days of market introduction, notifications for discontinued products within 1 year, and additional facility details upon FDA request within 10 days.
- Product Listing Number and Database: The FDA assigns a unique listing number to each product (which can cover similar variations like flavors). Within 2 years of enactment, the FDA must create a public, searchable electronic database with most listing information (excluding confidential business details like proprietary blend quantities or certain addresses).
- Compliance and Enforcement: Listings can be electronic. The FDA notifies submitters of receipt and completeness. Failure to list or update is considered misbranding (under section 403(z) of the FD&C Act), making the product illegal to sell. A new prohibited act (under section 301(jjj)) bans using debarred individuals in production.
- Confidentiality and Limitations: Trade secrets (e.g., proprietary blend amounts) are protected from public disclosure under Freedom of Information Act exemptions. The law does not allow FDA pre-market approval or expand inspection powers beyond existing authority.
- Funding: Authorizes $7.87 million for fiscal year 2026 and $6.62 million annually for 2027–2030 to implement the program, including hiring staff.
Significant Changes to Existing Law
- Amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding section 403D for mandatory listings, which did not previously exist for dietary supplements (unlike drugs or some foods).
- Expands misbranding rules (section 403) to include non-compliance with listing requirements.
- Adds a new prohibited act (section 301(jjj)) specifically targeting debarred persons in dietary supplement production, strengthening enforcement against unsafe practices.
- No changes to core dietary supplement regulations (e.g., no pre-market review), but builds on existing labeling rules under 21 CFR parts 101.
Potential Impacts
- Government Agencies: The FDA gains a centralized database to track products, potentially improving monitoring for safety issues, recalls, or adulteration without increasing pre-approval burdens. Implementation requires new resources and personnel, funded by the authorization.
- Citizens (Consumers): Enhances access to product details via a public database, helping consumers make informed choices about ingredients, claims, and allergens. Could indirectly improve safety by aiding faster identification of problematic products.
- International Relations: Minimal direct impact, but foreign manufacturers must appoint U.S. agents for listings, aligning with existing import rules and potentially easing FDA oversight of global supply chains.
Main Stakeholders Affected
- Manufacturers, Packers, and Distributors: Responsible for submitting and updating listings, facing compliance costs (e.g., electronic systems, record-keeping) but benefiting from a streamlined process for similar products.
- FDA: Tasked with database creation, review, and enforcement, with added administrative workload.
- Consumers and Retailers: Gain better transparency; retailers may need to verify listings to avoid selling misbranded products.
- Foreign Entities: Must comply via U.S. agents, affecting international supplement exporters.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces FDA's post-market oversight under the FD&C Act without violating the Dietary Supplement Health and Education Act of 1994 (which limits pre-market control). Protects proprietary information under trade secret laws (e.g., 18 U.S.C. § 1905) and FOIA exemptions, balancing transparency with business interests. Non-compliance leads to civil/criminal penalties as misbranding.
- Constitutional: No apparent conflicts; supports public health regulation under the Commerce Clause without infringing free speech (e.g., health claims are already regulated) or due process (clear compliance timelines and notifications provided).
- Political: Promotes consumer protection in a lightly regulated industry ($50+ billion market), potentially addressing concerns over supplement safety (e.g., undeclared ingredients). Bipartisan appeal in health policy, but may face industry pushback over administrative burdens; referred to Senate HELP Committee for review.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Durbin, Richard J. [D-IL]
Recent Actions
- 2026-01-15: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S259-260)
- 2026-01-15: Introduced in Senate
Bill Versions
- Dietary Supplement Listing Act of 2026 — issued 2026-01-15 — PDF (12 pages)